Literature DB >> 17667943

Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas.

E R Okawa1, T Gotoh, J Manne, J Igarashi, T Fujita, K A Silverman, H Xhao, Y P Mosse, P S White, G M Brodeur.   

Abstract

Neuroblastomas are characterized by 1p deletions, suggesting that a tumor suppressor gene (TSG) resides in this region. We have mapped the smallest region of deletion (SRD) to a 2 Mb region of 1p36.31 using microsatellite and single nucleotide polymorphisms. We have identified 23 genes in this region, and we have analysed these genes for mutations and RNA expression patterns to identify candidate TSGs. We sequenced the coding exons of these genes in 30 neuroblastoma cell lines. Although rare mutations were found in 10 of the 23 genes, none showed a pattern of genetic change consistent with homozygous inactivation. We examined the expression of these 23 genes in 20 neuroblastoma cell lines, and most showed readily detectable expression, and no correlation with 1p deletion. However, 7 genes showed uniformly low expression in the lines, and 2 genes (CHD5, RNF207) had virtually absent expression, consistent with the expected pattern for a TSG. Our mutation and expression analysis in neuroblastoma cell lines, combined with expression analysis in normal tissues, putative function and prior implication in neuroblastoma pathogenesis, suggests that the most promising TSG deleted from the 1p36 SRD is CHD5, but TNFRSF25, CAMTA1 and AJAP1 are also viable candidates.

Entities:  

Mesh:

Year:  2007        PMID: 17667943     DOI: 10.1038/sj.onc.1210675

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  44 in total

Review 1.  Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins.

Authors:  Alea A Mills
Journal:  Nat Rev Cancer       Date:  2010-10       Impact factor: 60.716

Review 2.  Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma.

Authors:  Louis Chesler; William A Weiss
Journal:  Semin Cancer Biol       Date:  2011-09-21       Impact factor: 15.707

3.  Molecular and cellular pathways associated with chromosome 1p deletions during colon carcinogenesis.

Authors:  Claire M Payne; Cheray Crowley-Skillicorn; Carol Bernstein; Hana Holubec; Harris Bernstein
Journal:  Clin Exp Gastroenterol       Date:  2011-05-03

4.  The tumor suppressor Chd5 is induced during neuronal differentiation in the developing mouse brain.

Authors:  Assaf Vestin; Alea A Mills
Journal:  Gene Expr Patterns       Date:  2013-10-09       Impact factor: 1.224

Review 5.  Ovarian cancer.

Authors:  Kathleen R Cho; Ie-Ming Shih
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

6.  The tumour suppressor CHD5 forms a NuRD-type chromatin remodelling complex.

Authors:  Venkatadri Kolla; Koumudi Naraparaju; Tiangang Zhuang; Mayumi Higashi; Sriharsha Kolla; Gerd A Blobel; Garrett M Brodeur
Journal:  Biochem J       Date:  2015-06-01       Impact factor: 3.857

Review 7.  Role of CHD5 in human cancers: 10 years later.

Authors:  Venkatadri Kolla; Tiangang Zhuang; Mayumi Higashi; Koumudi Naraparaju; Garrett M Brodeur
Journal:  Cancer Res       Date:  2014-01-13       Impact factor: 12.701

8.  Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer.

Authors:  Kylie L Gorringe; David Yh Choong; Louise H Williams; Manasa Ramakrishna; Anita Sridhar; Wen Qiu; Jennifer L Bearfoot; Ian G Campbell
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

9.  Chd5 requires PHD-mediated histone 3 binding for tumor suppression.

Authors:  Shilpi Paul; Alex Kuo; Thomas Schalch; Hannes Vogel; Leemor Joshua-Tor; W Richard McCombie; Or Gozani; Molly Hammell; Alea A Mills
Journal:  Cell Rep       Date:  2013-01-10       Impact factor: 9.423

10.  The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy.

Authors:  Nadine Van Roy; Katleen De Preter; Jasmien Hoebeeck; Tom Van Maerken; Filip Pattyn; Pieter Mestdagh; Joëlle Vermeulen; Jo Vandesompele; Frank Speleman
Journal:  Genome Med       Date:  2009-07-27       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.